Search / Trial NCT00001318

Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Dec 9, 2002

Trial Information

Current as of November 14, 2024

Completed

Keywords

Immune Adjuvant Phagocytes Non Tuberculous Mycobacterial Infection

ClinConnect Summary

This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. The study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. We may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.

Gender

ALL

Eligibility criteria

  • Demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary.
  • Received medical treatment for at least 3 months without improvement.
  • Preserved renal, hepatic and hematologic function.
  • Negative pregnancy urine and effective contraceptive.
  • Age range greater than 5.
  • No secondary immunodeficiency such as HIV or malignancy.
  • Not currently receiving cytotoxic therapy within the past 3 months.
  • Not pregnant or lactating.
  • No seizure disorders.
  • No known symptomatic cardiac disease.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials